Pharmacoeconomic review report : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)
Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with active, autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly formulation. The submitted price is $421.79 per 200 mg. At the recommended dosage of 200 mg weekly, the average annual cost is $21,933 per patient. Belimumab was previously reviewed by CADTH for the IV infusion. CADTH Canadian Drug Expert Committee (CDEC) recommended belimumab IV not be reimbursed because its clinical benefit was uncertain and its cost-effectiveness could not be adequately assessed..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
June 2020 |
|---|---|
| Erschienen: |
Ottawa (ON): CADTH ; June 2020 |
| Ausgabe: |
Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Adult |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 23, 2021) |
|---|
| Umfang: |
1 online resource (1 PDF file (29 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773183206 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773183206 | ||
| 003 | DE-627 | ||
| 005 | 20230428011910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773183206 | ||
| 035 | |a (DE-599)KEP068720106 | ||
| 035 | |a (NCBI)1774833 | ||
| 035 | |a (EBP)068720106 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pharmacoeconomic review report |b indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.) |
| 250 | |a Final (with redactions). | ||
| 264 | 1 | |a Ottawa (ON) |b CADTH |c June 2020 | |
| 300 | |a 1 online resource (1 PDF file (29 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 23, 2021) | ||
| 520 | |a Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with active, autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly formulation. The submitted price is $421.79 per 200 mg. At the recommended dosage of 200 mg weekly, the average annual cost is $21,933 per patient. Belimumab was previously reviewed by CADTH for the IV infusion. CADTH Canadian Drug Expert Committee (CDEC) recommended belimumab IV not be reimbursed because its clinical benefit was uncertain and its cost-effectiveness could not be adequately assessed. | ||
| 650 | 2 | |a Lupus Erythematosus, Systemic |x drug therapy |0 https://id.nlm.nih.gov/mesh/D008180Q000188 | |
| 650 | 2 | |a Adult |0 https://id.nlm.nih.gov/mesh/D000328 | |
| 650 | 2 | |a Immunosuppressive Agents |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D007166Q000627 | |
| 650 | 2 | |a Antibodies, Monoclonal, Humanized |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D061067Q000627 | |
| 650 | 2 | |a Immunosuppressive Agents |x economics |0 https://id.nlm.nih.gov/mesh/D007166Q000191 | |
| 650 | 2 | |a Treatment Outcome |0 https://id.nlm.nih.gov/mesh/D016896 | |
| 650 | 2 | |a Cost-Benefit Analysis |0 https://id.nlm.nih.gov/mesh/D003362 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 655 | 2 | |a Review |0 https://id.nlm.nih.gov/mesh/D016454 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK564629/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994080312 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994006562 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999782838 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995675506 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987672722 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987761822 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK564629/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK564629/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK564629/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK564629/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK564629/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||